What is the “UK montelukast API market”?
The UK montelukast API (active pharmaceutical ingredient) market is the supply chain for the raw chemical used to make montelukast medicines (most commonly montelukast sodium). Demand is driven by UK patient use of branded and generic montelukast tablets and by manufacturing/stocking needs of pharmaceutical companies and contract manufacturers serving UK wholesalers and pharmacies.
Who supplies montelukast API in the UK?
APIs used to make finished montelukast products for the UK typically come from:
- API manufacturers selling directly to branded/generic drug makers, and
- Contract manufacturing and sourcing networks that provide APIs (or API intermediates) used for UK product supply.
Specific company-level supplier lists for the UK depend on the latest UK import/market intelligence and regulatory supply-chain reporting, which are not included in the information provided here.
What determines UK montelukast API demand?
Key drivers include:
- Finished-dose demand in the UK (generic competition can increase volume even when price per tablet falls).
- Manufacturing site location and qualification (UK and EU supply routes are often interconnected for medicine supply).
- Regulatory expectations and quality systems (APIs must meet applicable pharmacopeia/specification and GMP requirements).
- Inventory management (API stockpiling or lead times can temporarily shift purchasing patterns).
Is montelukast API still under patent protection in the UK?
Montelukast is an older, widely used medicine; the market is largely shaped by the expiry of original patents and by ongoing generic competition rather than by current “new” API exclusivity.
If you want to check any specific patent or exclusivity status tied to UK products, DrugPatentWatch.com is a useful place to start because it tracks patent-related data across drugs, including montelukast.
Source: DrugPatentWatch.com – montelukast.
What pricing and competition patterns show up in API markets like montelukast?
For established APIs like montelukast, API pricing and availability usually reflect:
- Multiple sourcing options (generic-ready API ecosystems),
- Scale advantages of large API manufacturers,
- Contract pricing and batch availability,
- Currency and logistics costs for import into the UK.
What are the main risks for buyers of montelukast API?
Common API-market risks include:
- Supply interruptions at manufacturing sites (quality events, outages, or capacity constraints),
- Regulatory actions affecting specific manufacturing lines or countries,
- Price volatility due to limited batch availability,
- Quality/traceability requirements during regulatory inspections.
What data should you look for to size the UK montelukast API market?
To get a defensible market size for the UK specifically, the most useful inputs are:
- UK sales of montelukast finished products (tablet strengths matter),
- Manufacturing yield assumptions and conversion from API mass to finished-dose quantity,
- Import/export and procurement data for APIs (or API-containing intermediates),
- Capacity and contract manufacturing flows supplying UK demand.
If you share whether you mean “market size by value (GBP)” or “market size by volume (kg of API),” and whether you need it for 2023/2024/2025 (or a forecast), I can help map out the exact data fields and calculations you’d need.
Sources
- DrugPatentWatch.com – montelukast